MedPath

Melody PB1016 Surveillance Study

Not Applicable
Completed
Conditions
Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects
Interventions
Device: Melody Transcatheter Pulmonary Valve PB1016
Registration Number
NCT02347189
Lead Sponsor
Medtronic Heart Valves
Brief Summary

Non-randomized, multi-center, prospective surveillance study to investigate and assess the residual risks, and to confirm the currently established safety and performance of the Melody TPV PB1016.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • Patient eligible to receive Melody TPV PB1016 per current Instructions for Use (IFU) indications at time of study enrollment
  • Patient (or patient's legally authorized representative) is willing to consent to participate in the study and will commit to completion of all follow-up requirements.
Exclusion Criteria
  • Implantation in the aortic, tricuspid, or mitral position
  • Venous anatomy unable to accommodate a 22-Fr size introducer sheath
  • Obstruction of the central veins
  • Clinical or biological signs of infection including active endocarditis
  • History of intravenous substance abuse
  • Currently participating in an investigational drug or device study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Melody TPV PB1016Melody Transcatheter Pulmonary Valve PB1016-
Primary Outcome Measures
NameTimeMethod
Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months6 Months

Acceptable TPV hemodynamic function at six months after successful TPV implantation which is determined as a composite of the following:

* Mean Right Ventricular Outflow Tract (RVOT) gradient is less than or equal to 30 mmHg as measured by Continuous-wave Doppler (CW Doppler) echocardiography, and

* Severity of pulmonary regurgitation less than moderate by CW Doppler echocardiography, and

* Free from RVOT conduit reoperation or catheter re-intervention on the TPV at six months post-TPV implantation

Secondary Outcome Measures
NameTimeMethod
Number of Subjects With Serious Procedure-related and Device-related Adverse Events1 Year, 2 Years

* Serious procedure-related adverse events at 1year and 2 years post-implant

* Serious device-related adverse events at 1 year and 2 years post-implant

Number of Subjects With Procedural SuccessAt Time Of Procedure

A successful implant is defined as follows:

* Melody TPV PB1016 is fixated within the desired location

* RV-PA peak-to-peak gradient measured in the catheterization lab after Melody TPV PB1016 implantation is \< 35 mmHg

* No more than trace/trivial pulmonary regurgitation by angiography

* Subject is free from explantation of the Melody TPV PB1016 at 24 hours post-implant.

Percentage of Participants Who Met Various Safety Parameters of the Melody TPV PB10162 years

* Kaplan-Meier: Freedom from Stent Fracture

* Kaplan-Meier: Freedom from re-intervention on the Melody TPV PB1016

* Kaplan-Meier: Freedom from RVOT Conduit Operation

* Kaplan-Meier: Freedom from Death (All-Cause)

Number of Subjects With Acceptable TPV Hemodynamic Function At 1 Year1 Year

Acceptable TPV hemodynamic function at 1 year after successful TPV implantation which is determined as a composite of the following:

* Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler

* Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography

* Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 1 year post-TPV implantation.

Number of Subjects With Acceptable TPV Hemodynamic Function at 2 Years2 Years

Acceptable TPV hemodynamic function at 2 years after successful TPV implantation which is determined as a composite of the following:

* Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler

* Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography

* Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 2 years post-TPV implantation.

Trial Locations

Locations (8)

Landes-Kinderklinik

🇦🇹

Linz, Austria

Hospital General Universitario Gregorio Marañón

🇪🇸

Madrid, Spain

Children's Hospital of Michigan

🇺🇸

Detroit, Michigan, United States

University of California - Los Angeles

🇺🇸

Los Angeles, California, United States

Stollery Childrens Hospital

🇨🇦

Edmonton, Alberta, Canada

Seattle Childrens and Regional Hospital

🇺🇸

Seattle, Washington, United States

Nationwide Childrens Hospital

🇺🇸

Columbus, Ohio, United States

Primary Children's Hospital

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath